Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

Uveitis Clinical Trial

Official title: Study of TNF-α Inhibitor Reduction or Discontinuation in Patients With Non-infectious Uveitis

Status Recruiting

Clinical Trial Summary

TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use can increase the risk of drugs, and the patient's financial burden is large. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis.

Clinical Trial Description

TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use will increase the risk of drugs, and the patient's financial burden is large. Previous studies have reported that tapering or discontinuation of Adalimumab may be considered in patients with stable disease. In clinical practice, some important questions about the feasibility of dose reduction in individual patients and the withdrawal plan remain unanswered. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis. ;

Related Conditions & MeSH terms

• Adalimumab
• Uveitis

• NCT number: NCT05155592
• Study type: Interventional
• Source: Sun Yat-sen University
• Contact: Dan Liang, PhD
• Phone: 0086-20-87330402
• Email: liangd2@mail.sysu.edu.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2021
• Completion date: April 1, 2023